The development of novel small molecule therapeutics has long been constrained by fundamental limitations in molecular exploration. Traditional approaches screen thousands of compounds to identify a single viable candidate and often fail to account for the intricacies of drug-target interactions, leading to high attrition rates in clinical trials.
READ MOREWhat if you could predict the next breakthrough molecule before your competitors even begin screening?
READ MOREThe most profound revolutions don't announce themselves with fanfare. They creep up quietly, rewiring civilisation before we've even noticed. Now, another quiet revolution is unfolding: the rise of AI Factories.
READ MOREWe are witnessing a fundamental shift in how computing infrastructure is designed and deployed. Find out how you can stay ahead of the curve with Boston and NVIDIA.
READ MORETo help our clients make informed decisions about new technologies, we have opened up our research & development facilities and actively encourage customers to try the latest platforms using their own tools and if necessary together with their existing hardware. Remote access is also available
Boston Germany are exhibiting at AFCEA Bonn 2025!